DTX2 and neoplasm: Recently, several studies suggest that the inhibition of specific ubiquitin ligases may be beneficial for the response to immunotherapy.[7, 8] Deltex E3 ubiquitin ligase 2 (DTX2) can recognize and promote the ubiquitination of proteins with polyadenosine diphosphate ribosylation (poly‐ADP‐ribosylation, PARylation) through its DTC domain.[9] In addition, DTX2 participates in different types of ubiquitination modifications.[10, 11] However, the specific role of DTX2 in the tumor immune microenvironment remains unknown.